Frequently Asked Questions
About Hizentra

What's the difference between intravenous Ig (IVIg) therapy and subcutaneous Ig (SCIg) therapy?

Ig therapy is generally delivered in two basic ways. Intravenous Ig therapy, or IVIg, is administered into the vein by a medical professional about every 3 to 4 weeks.

Subcutaneous Ig therapy, or SCIg, is infused under the skin, using a small needle and an infusion pump. With proper training, most patients can self-infuse SCIg. Most SCIg products are infused once a week, but Hizentra is unique in giving you the option to infuse on a schedule that works for you -- as often as daily or up to once every 2 weeks. Talk with your healthcare provider about the dosing option that's right for you.

After I am trained on self-administration, will I still need to go to my healthcare provider?

Yes. Partnering with one's healthcare provider is necessary for patients with primary immune deficiency disease (PI or PIDD). Regular healthcare provider visits are an important part of your therapy program. At each visit, your healthcare provider will evaluate your dose and your response to treatment and address any concerns you may have. It's important to bring your Hizentra therapy journal, or send infusion records via the MyHizentra™ Infusion Manager app, to share with your healthcare provider.

What are the benefits of a high Ig concentration?

As a 20% IgG therapy, Hizentra has the highest concentration of immunoglobulin available in an Ig treatment, so you can receive the IgG your body needs while infusing a low volume, which potentially results in fewer needle sticks. Hizentra was specifically designed to deliver steady-state IgG levels in half the volume of 10% Ig products,* regardless of which dosing schedule you and your healthcare provider choose.

*Based on an equivalent dose in grams

How long can I store Hizentra at room temperature?

Hizentra can be stored at room temperature (up to 25°C [77°F]) for its entire shelf life, up to 30 months.

Will my insurance cover the cost of Hizentra?

We are working to have Hizentra covered by as many health insurance formularies as possible. We can also help you identify managed care reimbursement opportunities and financial assistance if you're uninsured.

How much does Hizentra cost?

The cost of any treatment, including Hizentra, depends on a number of factors, including insurance status and the insurers' co-pay/coinsurance policy. The actual out-of-pocket cost to a patient will depend on their individual prescription or medical coverage.

For those who cannot afford their treatment, CSL Behring is committed to providing appropriate resources to ensure patients can begin and/or remain on their therapy. These include:

CSL Behring AssuranceSM — The CSL Behring Assurance Program is free and features easy enrollment and participation. The program allows you to earn points for Hizentra that you can use to secure product should you have a lapse in your third-party, private health insurance.

CSL Behring Patient Assistance ProgramSM — The CSL Behring Patient Assistance Program may help if you are uninsured or underinsured, or otherwise can't afford SCIg therapy. If you qualify, you may receive up to a 3-month supply of a SCIg therapy. At the end of 3 months, your eligibility is reevaluated for continued participation. If you have an emergency need for SCIg therapy, it will be addressed under a separate process when the call is received within 24 hours of the emergency.

Hizentra Co-Pay Relief Program – The Hizentra Co-Pay Relief program helps eligible patients afford their therapy by helping with monthly out-of-pocket expenses for Hizentra (up to $5,000 for one year, with no monthly cap).*

To be eligible:

  • Prescription must be for primary immunodeficiency diagnosis
  • Patients must be at least 2 years of age
  • Patient must be receiving Hizentra through a specialty pharmacy or physician office
  • Patient must express financial need
  • Patient must have coverage for the product under a private US insurance plan. Not valid for prescriptions eligible for reimbursement by any federal or state healthcare program, such as Medicare, Medicare advantage plans, Medicaid, PCIP, Champus, TriCare, Veterans Administration (VA), or any other state or federal program
  • Patients whose insurance policy prohibits co-pay assistance are not eligible
  • This program is subject to change or discontinuation by CSL Behring at any time, for any reason, and with or without prior notice
  • Hizentra Co-Pay Relief program is administered by Medmonk Inc.; terms and conditions apply

Simply contact CSL Behring's IgIQ resource hotline at 1-877-355-IGIQ (4447), Monday-Friday, 8 AM to 8 PM ET to confirm eligibility and learn about next steps.

*This program applies to product costs only; however, assistance for infusion-related costs may be available through a non profit patient support organization. Contact IgIQ to learn more.

†Prior to enrolling in this CSL Behring program, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their insurance carrier's requirements.

For more information, call the IgIQ Resource Center, CSL Behring's single source for information about immunoglobulin therapies, at 1-877-355-IGIQ (4447), Monday-Friday, 8 AM to 8 PM ET.

Ig Therapy Designed for Freedom
& Flexibility

Hizentra is the first and only 20% SCIg therapy with multiple flexible dosing options, enabling you to infuse at regular intervals from daily up to every 2 weeks, depending on what fits your lifestyle. Hizentra is available in 4 vial sizes, including a 10 g (50 mL) vial.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and MyHizentra® are registered trademarks of CSL Behring AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM, IgIQSM, and Premier StartSM are service marks of CSL Behring LLC.
Voice2Voice® is a registered trademark of CSL Behring GmbH.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0316-MAR18